A deeply discounted, post-pivot biotech: blockbuster-grade HCC survival data plus dual-target CAR‑T optionality—balanced by brutal Phase 3 and funding binaries.
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company that has recently executed a fundamental strategic pivot, transitioning from a pure-play small molecule oncology firm to a diversified developer of both first-in-class metabolic modulators and next-generation cell therapies.[1, 2] The company’s operational framework is centered on the discovery and development of therapeutics that address the limitations of current immune-oncology treatments by targeting the underlying metabolic adaptations of cancer cells and the immunosuppressive nature of the tumor microenvironment.[3, 4, 5] Following the strategic acquisition of a portfolio of dual-targeting chimeric antigen receptor (CAR)-T assets from Factor Bioscience Inc. and Erigen LLC in early 2026, Tempest has significantly expanded its pipeline, positioning itself at the forefront of the treatment of hematologic malignancies and solid tumors.[1, 2, 6]
The company’s revenue model is typical of a clinical-stage biopharmaceutical entity, characterized by the absence of current product sales and a reliance on strategic collaborations, milestone payments, and capital markets for funding.[7, 8, 9] Current and near-term potential revenue streams are derived from partnerships, most notably with Novatim Immune Therapeutics in China, which oversees and funds the development of the lead CAR-T asset, TPST-2003, in that territory.[10, 11, 12] Under this arrangement, Tempest stands to benefit from clinical data sharing, which de-risks its own planned registrational studies in the United States, and potentially from future milestones or royalties if commercialization occurs in the partner’s territories.[2, 6] Furthermore, the company leverages non-dilutive funding sources, such as the National Cancer Institute (NCI), which is funding the Phase 2 clinical trial of the small molecule candidate TPST-1495 for familial adenomatous polyposis (FAP).[2, 13]
Tempest’s key market segments include the global hepatocellular carcinoma (HCC) market, valued at approximately $5.2 billion in 2026 and projected to reach $9.4 billion by 2033, and the rapidly growing CAR-T cell therapy market, which is estimated to reach $13.78 billion by 2031.[14, 15, 16] The lead small molecule candidate, amezalpat (TPST-1120), is a first-in-class PPARα antagonist that has demonstrated superior clinical efficacy in combination with the standard-of-care regimen for first-line HCC, showing a six-month improvement in median overall survival during randomized Phase 1b/2 testing.[1, 17, 18] The lead CAR-T asset, TPST-2003, targets relapsed/refractory multiple myeloma (rrMM), with a specific focus on patients with extramedullary disease (EMD), a segment of high unmet need where existing therapies often fail to provide durable responses.[10, 11, 12] Through this dual-platform approach, Tempest seeks to address a broad spectrum of oncology patients, ranging from those with common solid tumors to those with orphan genetic conditions and refractory blood cancers.[6, 17, 19]
The primary value drivers for Tempest Therapeutics are rooted in the successful clinical progression of its high-impact oncology assets and the execution of its capital-efficient development strategy.[1, 20] The company’s strategic outlook has been revitalized by the 2026 acquisition of CAR-T assets, which provided not only a new therapeutic platform but also a critical extension of the operational cash runway through investment commitments from Factor Bioscience.[2] This transition allows Tempest to simultaneously pursue late-stage small molecule development while building a leadership position in engineered cell therapy.[1, 6, 20]
Amezalpat’s competitive advantage is derived from its unique status as a first-in-class antagonist of peroxisome proliferator-activated receptor alpha (PPARα).[3, 5] While many oncology drugs focus on surface-level receptors or DNA repair, amezalpat targets the metabolic core of the tumor.[4, 21] Cancer cells in the liver and kidney frequently upregulate fatty acid oxidation (FAO) as a primary energy source, a process regulated by PPARα.[3, 5] By blocking this pathway, amezalpat induces metabolic stress in the tumor and simultaneously reprograms the tumor microenvironment to be more receptive to the immune system by inhibiting suppressive M2 macrophages and myeloid-derived suppressor cells.[3, 5]
The strategic importance of amezalpat is underscored by its clinical performance in the Phase 1b/2 Morpheus-Liver study, conducted in collaboration with Roche.[3, 19] The addition of amezalpat to the standard combination of atezolizumab and bevacizumab resulted in a median overall survival of 21 months versus 15 months for the control group, representing a 35% reduction in the risk of death (Hazard Ratio: 0.65).[1] This superiority was particularly evident in patients with β-catenin mutations and PD-L1 negative tumors, segments that represent a significant portion of the HCC population and are traditionally difficult to treat.[13, 17, 18] With broad regulatory alignment from the FDA, EMA, and China's NMPA, amezalpat is positioned for a global Phase 3 pivotal study, which, if successful, could establish it as a standard component of first-line HCC treatment.[1, 22, 23]
The introduction of TPST-2003 into the Tempest pipeline addresses the critical challenge of antigen escape in multiple myeloma.[10, 12] While current FDA-approved CAR-T therapies such as Carvykti and Abecma target BCMA, patients frequently relapse when the cancer evolves to downregulate this single target.[24, 25, 26] TPST-2003 utilizes a parallel dual-targeting architecture that attacks both CD19 and BCMA simultaneously.[6, 10] This dual-pronged approach is specifically designed to treat high-risk patients, including those with extramedullary disease (EMD), who typically exhibit a poorer prognosis.[10, 11, 27]
The efficacy data from investigator-initiated trials in China are unprecedented, showing a 100% hematologic objective response rate in 18 patients and durable disease control with a median progression-free survival of 23.1 months.[1, 11, 12] Tempest’s strategy for TPST-2003 is highly capital-efficient: development in China is fully funded by Novatim Immune Therapeutics, while Tempest retains global rights for North America and Europe, with plans to initiate a U.S. registrational study in 2027.[2, 6] This "reference-based" regulatory approach allows Tempest to utilize offshore clinical data to support its own filings, significantly reducing the financial burden of early-stage clinical work.[2]
Tempest operates in markets with high barriers to entry but significant commercial rewards.[28, 29] The HCC market is undergoing a shift toward combination therapies, where amezalpat fits as a potentially synergistic additive.[14, 30] In the multiple myeloma space, the company faces competition from established pharmaceutical giants, but its focus on EMD and its dual-antigen targeting provide a clear clinical niche.[24, 26] The rise of MASLD-linked HCC cases in high-income economies and the increasing prevalence of relapsed hematologic malignancies ensure a steady and growing demand for the company’s product candidates.[28, 31, 32]
| Asset | Target Indication | Primary Advantage | Funding/Partnership |
|---|---|---|---|
| Amezalpat | 1L Hepatocellular Carcinoma | First-in-class PPARα inhibitor; improves OS by 6 months in Phase 2. | Global Rights; Phase 3 ready. |
| TPST-2003 | rrMultiple Myeloma | Dual CD19/BCMA targeting; 100% ORR in EMD patients. | Partner-funded in China (Novatim). |
| TPST-1495 | Familial Adenomatous Polyposis | Precision EP2/EP4 dual antagonist. | Fully funded by NCI. |
| TPST-2206 | Renal Cell Carcinoma | Dual CD70/CD70 targeting CAR-T. | Preclinical; acquired from Factor. |
[1, 2, 10, 13]
Tempest Therapeutics’ financial narrative in 2025 was one of strategic survival followed by a transformative recapitalization in early 2026.[33, 34, 35] The company entered 2025 with $30.3 million in cash but faced an immediate need to "explore strategic alternatives" due to the high cost of the amezalpat Phase 3 program.[9, 34] This led to a deliberate curtailment of research activities in mid-2025, where R&D expenses dropped from $7.6 million in Q3 2024 to just $0.6 million in Q3 2025.[8] This austerity measure was critical in preserving the remaining capital while the board negotiated the acquisition of the CAR-T platform.[2, 35]
For the full year 2025, Tempest recorded a substantial net loss, though the loss per share showed improvement on a year-over-year basis due to the 1-for-13 reverse stock split effective in April 2025.[36, 37, 38] The net loss for the nine months ended September 30, 2025, was $22.2 million, or $5.71 per share, compared to a net loss of $28.0 million, or $15.48 per share, in the prior year.[8]
| Financial Metric (in thousands, except per share) | Q3 2025 | 9mo 2025 | FY 2024 (9mo) |
|---|---|---|---|
| Total Revenue | $0 | $0 | $0 |
| Research & Development | $570 | $12,067 | $17,734 |
| General & Administrative | $3,027 | $10,431 | $10,374 |
| Net Loss | ($3,511) | ($22,241) | ($28,030) |
| Cash and Cash Equivalents | $7,514 | $7,514 | $30,268 |
| Accumulated Deficit | ($229,347) | ($229,347) | ($207,106) |
[8, 9, 35]
The cash burn rate was moderated through the second half of 2025 as the company prioritized the Factor Bioscience transaction.[2, 8] The completion of a $4.6 million registered direct offering in June 2025 and $2.8 million in net proceeds from an at-the-market (ATM) program provided enough liquidity to bridge the company to the February 2026 closing of the CAR-T acquisition.[8, 35]
As of March 2026, Tempest’s valuation remains in a state of flux. The stock price, trading in the $1.65–$1.75 range, reflects a market capitalization of roughly $24.81 million.[33, 39, 40, 41] However, this valuation does not appear to reflect the intrinsic value of its two lead clinical programs.[42, 43, 44]
Using the Risk-Adjusted Net Present Value (rNPV) methodology common in biotech valuation, amezalpat’s potential can be calculated based on an estimated $600 million peak sales in HCC, a 25% probability of Phase 3 success (POS), and a 15% discount rate.[46, 48] This alone would justify a valuation significantly higher than the current market cap. When the CAR-T platform is added—valued as a Series B stage equivalent at approximately $150 million [46]—the gap between Tempest’s market price and its fundamental value becomes highly pronounced.
Tempest Therapeutics faces a myriad of risks that are common to small-cap biotechnology firms but are amplified by its ambitious dual-platform strategy and history of liquidity constraints.[2, 7, 34]
The success of Tempest is fundamentally tied to the outcome of its Phase 3 trial for amezalpat.[23, 49] While Phase 2 data were compelling, the liver cancer patient population is notoriously difficult to treat due to underlying comorbidities such as cirrhosis and viral hepatitis.[28, 29] Any adverse safety signal or failure to replicate the survival benefit in the larger 740-patient study would result in a total loss of value for the amezalpat program.[28, 49] Similarly, while TPST-2003 has shown 100% ORR in China, the U.S. FDA may require more extensive domestic data before granting approval, and the complexity of autologous CAR-T manufacturing remains a significant potential choke point.[10, 24, 26]
Tempest remains a "going concern" that will require hundreds of millions of dollars in additional capital to reach commercialization.[2, 34] Although the Factor Bioscience commitment extends the runway to mid-2027, the company will almost certainly need to tap the equity markets again.[2] In a high-interest-rate environment, the cost of this equity is expensive, and further dilutive financings could severely diminish the returns for current stockholders.[45, 50, 51] Furthermore, the company’s recent history of Nasdaq non-compliance regarding its annual meeting schedule indicates a level of administrative strain that investors must consider.[52]
The multiple myeloma market is one of the most competitive segments of oncology.[16, 29] Tempest must compete with the massive commercial reach of companies like Johnson & Johnson, Gilead, and Bristol Myers Squibb.[24, 26] Macroeconomic shifts, such as changes in Medicare reimbursement policies for expensive cell therapies or a broader economic downturn that reduces the availability of venture-debt and secondary offerings, could cripple the company’s ability to fund its pipeline.[29, 30, 45]
| Risk Category | Impact | Mitigation Strategy |
|---|---|---|
| Clinical Failure | High | Diversification into CAR-T; partner-funded studies in China. |
| Cash Burn/Dilution | High | Use of NCI/Partner funding; strategic investment from Factor. |
| Competition | Medium | Niche focus on EMD-myeloma; first-in-class MoA in HCC. |
| Regulatory Delay | Medium | Utilization of Fast Track and Orphan Drug designations. |
[2, 10, 13, 18, 22]
The following scenarios analyze the potential return for Tempest Therapeutics from 2026 to 2031. These projections are based on current clinical timelines, market size forecasts, and standard biotech valuation multiples.[14, 15, 45, 46]
| Year | High Case ($) | Base Case ($) | Low Case ($) |
|---|---|---|---|
| 2026 (Launch) | $1.70 | $1.70 | $1.70 |
| 2027 (IND Filed) | $7.25 | $4.50 | $1.20 |
| 2028 (Ph3 Interim) | $16.80 | $9.20 | $0.85 |
| 2029 (US BLA TPST-2003) | $31.40 | $15.75 | $0.60 |
| 2030 (Amezalpat Approval) | $46.90 | $20.10 | $0.45 |
| 2031 (Five-Year Target) | $58.50 | $24.75 | $0.35 |
| Scenario | Subjective Probability | 2031 Target Price | Weighted Value |
|---|---|---|---|
| High Case | 20.00% | $58.50 | $11.70 |
| Base Case | 50.00% | $24.75 | $12.38 |
| Low Case | 30.00% | $0.35 | $0.11 |
| Probability Weighted Target | $24.19 |
ASYMMETRIC VOLATILE ALPHA
The board and executive team demonstrate exceptional skin-in-the-game. CEO Matthew Angel’s 37.4% beneficial stake and his repeated open-market purchases at prices above the current market signal deep conviction in the newly integrated pipeline.[33, 41, 53] Compensation is heavily weighted toward stock options, further aligning their interests with those of long-term investors.[52, 54]
As a pre-revenue biotech, the current "revenue" is non-existent. Future revenue depends entirely on high-risk clinical outcomes and regulatory approvals.[7, 8] The reliance on third-party funding (NCI/Partners) is a positive sign of asset validation but does not yet represent high-quality, recurring cash flow.[2, 13]
Tempest is winning in terms of differentiation. Amezalpat is a "first-in-class" metabolic modulator with no direct competitors in the PPARα oncology space.[3, 5] In CAR-T, the parallel dual-antigen targeting provides a clear advantage in treating heterogeneous and refractory multiple myeloma.[10, 11]
The pipeline is rich with catalysts. Beyond the lead assets, the acquisition brought in preclinical allogeneic CAR-T and in vivo CAR-T programs that address the next frontier of oncology and autoimmune diseases.[2, 11, 20]
The company remains fragile. While the mid-2027 runway is a vast improvement, the total capital required for Phase 3 and registrational success far exceeds current resources.[2, 34] The accumulated deficit of over $229 million highlights the expensive nature of their R&D.[8]
The durability of the business is high if clinical success is achieved, as the intellectual property protection and Orphan Drug status provide multi-year monopolies.[2, 17, 18] However, a failure in the amezalpat Phase 3 would be a catastrophic event for the company's viability.[34]
Management has shown agility in pivoting away from pure cash-burn small molecule work to a more diversified, partner-supported model.[1, 2, 20] The 2026 acquisition was a masterstroke in survival, though previous stockholders were heavily diluted by the reverse split.[36, 37]
Despite the low share price, analysts who cover the stock are overwhelmingly bullish, focusing on the rNPV of the assets rather than the temporary financing overhang.[42, 43, 44, 55]
The company is currently generating significant losses and is years away from GAAP profitability.[8, 42]
The historical track record is marred by the 1-for-13 reverse split and Nasdaq compliance issues.[36, 38, 52] However, the "New Tempest" under Matthew Angel has shown a more disciplined and strategic approach to asset acquisition and funding.[2, 33]
OVERALL BLENDED SCORE: 5.2 / 10
TRANSFORMATIVE SPECULATIVE OPPORTUNITY
Tempest Therapeutics, Inc. represents a unique clinical-stage investment vehicle that has recently been fundamentally de-risked and diversified through the acquisition of a next-generation CAR-T platform.[1, 2, 6] The company’s core thesis is predicated on the ability of its lead asset, amezalpat, to improve survival in the multi-billion dollar HCC market and the potential for TPST-2003 to dominate the niche segment of extramedullary multiple myeloma.[1, 10, 11, 17]
Strategic Highlights and Catalysts:
* Unrivaled Clinical Signal: Amezalpat’s 21-month OS vs. 15-month SoC is one of the strongest Phase 2 signals in the history of HCC drug development.[1]
* Dual-Antigen Superiority: TPST-2003’s 100% ORR in high-risk patients suggests it could become a preferred therapy for rrMM patients who fail single-antigen BCMA therapies.[11, 12]
* Insider Conviction: The massive personal investment and beneficial ownership stake held by the CEO provide a significant "margin of safety" for investors concerned about agency risk.[33, 41]
* Funding Efficiency: The partner-funded model in China and NCI-funded FAP program allow Tempest to maintain "shots on goal" while focusing its internal capital on U.S. registrational paths.[2, 10, 13]
The primary risk remains the clinical binary—Phase 3 trials are notoriously unforgiving.[28, 49] However, for investors with a five-year horizon and a tolerance for high-volatility clinical risk, the current valuation gap between the market price (~$1.70) and the probability-weighted intrinsic value (~$24.00) represents a significant opportunity for alpha generation.[33, 42, 43, 44]
BIPHASIC CLINICAL CATALYST
Tempest Therapeutics is currently in a severe technical downtrend, trading at $1.66 and well below its 200-day simple moving average of $6.29.[39, 56] The stock recently broke down from its falling trend channel, indicating extreme investor pessimism, though the 14-day RSI of 27.48 suggests the shares are in deep oversold territory.[41, 53, 57] Short-term support is non-existent, and any recovery will face immediate resistance at the $1.94 and $2.26 levels.[53] The short-term outlook is negative until the market sees concrete steps toward Phase 3 initiation for amezalpat or further U.S. IND progress for TPST-2003.
OVERSOLD TECHNICAL DRIFT
View Tempest Therapeutics, Inc. (TPST) stock page
Loading the interactive version of this report…